Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Fosun
Fosun
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Fosun Pharma invests $50m in BioNTech for its COVID-19 vaccine
The two companies have agreed to develop BNT162 in China leveraging Fosun’s capabilities in the country
Finance
Chinese facility changes hands from GSK to Fosun Pharmaceutical
The deal has been reported to be worth US$36 million
Finance
ReNeuron and Fosun Pharma join forces in China
For exclusive rights to its CTX and hRPC cell therapy programmes, ReNeuron will receive £6 million upfront, and approximately £80 million in milestone payments
Regulatory
Sirona Biochem announces SGLT2 IND submission
Sirona Biochem announced its partner Wanbang Biopharmaceuticals has confirmed an investigational new drug (IND) submission to China's Food and Drug Administration (CFDA) for its SGLT2 inhibitor
Subscribe now